tetano
Editor, Senior Moderator
Hematol Transfus Cell Ther
. 2021 Dec 15.
doi: 10.1016/j.htct.2021.09.020. Online ahead of print.
Proportion of Hematological Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic: a Systematic Review and Meta-Analysis
Mohammadali Jafari[SUP] 1 [/SUP], Seyed Alireza Dastgheib[SUP] 2 [/SUP], Farzad Ferdosian[SUP] 1 2 [/SUP], Hamid Mirjalili[SUP] 1 [/SUP], Hossein Aarafi[SUP] 3 [/SUP], Mahmood Noorishadkam[SUP] 1 [/SUP], Mahta Mazaheri[SUP] 1 [/SUP], Hossein Neamatzadeh[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: The coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of the cancer patient.
Objective: The aim of this meta-analysis was to evaluate the proportion of hematological cancer patients with the SARS-CoV-2 infection during the COVID-19 pandemic.
Method: A comprehensive literature review was performed on PubMed, Web of Science, Scopus, EKB SciELO, SID, CNKI and Wanfang databases to retrieve all relevant publications up to January 31, 2021. Observational studies, consecutive case-series and case-control studies were included. The proportion for hematological cancer patients with COVID-19 was estimated using the odds ratios (ORs) and 95% confidence interval (95% CIs).
Results: Fourteen studies with a total of 3,770 infected cancer patients and 685 hematological cancer cases with COVID-19 were selected. Combined data revealed that the overall proportion of hematological cancer patients with COVID-19 was 16.5% (95% CI 0.130 - 0.208, p ≤ 0.001). The stratified analysis by ethnicity showed that the proportion was 18.8% and 12.4% in Caucasian and Asian hematological cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that its proportion was the highest in the United Kingdom (22.5%), followed by France (17.1%) and China (8.2%).
Conclusion: This meta-analysis result indicated that the proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 16.5%. Further larger sample sizes and multicenter studies among different ethnic groups are necessary to get a better assessment of the proportion.
Keywords: COVID-19; Hematological Cancer; Infection; Pandemic; SARS-CoV-2.
. 2021 Dec 15.
doi: 10.1016/j.htct.2021.09.020. Online ahead of print.
Proportion of Hematological Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic: a Systematic Review and Meta-Analysis
Mohammadali Jafari[SUP] 1 [/SUP], Seyed Alireza Dastgheib[SUP] 2 [/SUP], Farzad Ferdosian[SUP] 1 2 [/SUP], Hamid Mirjalili[SUP] 1 [/SUP], Hossein Aarafi[SUP] 3 [/SUP], Mahmood Noorishadkam[SUP] 1 [/SUP], Mahta Mazaheri[SUP] 1 [/SUP], Hossein Neamatzadeh[SUP] 1 [/SUP]
Affiliations
- PMID: 34931178
- PMCID: PMC8673822
- DOI: 10.1016/j.htct.2021.09.020
Abstract
Introduction: The coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of the cancer patient.
Objective: The aim of this meta-analysis was to evaluate the proportion of hematological cancer patients with the SARS-CoV-2 infection during the COVID-19 pandemic.
Method: A comprehensive literature review was performed on PubMed, Web of Science, Scopus, EKB SciELO, SID, CNKI and Wanfang databases to retrieve all relevant publications up to January 31, 2021. Observational studies, consecutive case-series and case-control studies were included. The proportion for hematological cancer patients with COVID-19 was estimated using the odds ratios (ORs) and 95% confidence interval (95% CIs).
Results: Fourteen studies with a total of 3,770 infected cancer patients and 685 hematological cancer cases with COVID-19 were selected. Combined data revealed that the overall proportion of hematological cancer patients with COVID-19 was 16.5% (95% CI 0.130 - 0.208, p ≤ 0.001). The stratified analysis by ethnicity showed that the proportion was 18.8% and 12.4% in Caucasian and Asian hematological cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that its proportion was the highest in the United Kingdom (22.5%), followed by France (17.1%) and China (8.2%).
Conclusion: This meta-analysis result indicated that the proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 16.5%. Further larger sample sizes and multicenter studies among different ethnic groups are necessary to get a better assessment of the proportion.
Keywords: COVID-19; Hematological Cancer; Infection; Pandemic; SARS-CoV-2.